Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-11-15 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". Form 8.3 is a mandatory disclosure required under the UK Takeover Code when a person holding interests in relevant securities of an offeror or offeree reaches or crosses the 1% threshold during an offer period. This form details the person's position and any dealings related to the securities involved in the takeover situation. This specific disclosure relates to dealings by Millennium International Management LP concerning Dechra Pharmaceuticals plc, which is subject to a takeover. While it involves director/insider-like activity (related to a takeover), the most precise classification for disclosures related to takeover rules and insider positions during an offer period, especially when dealing with specific forms like 8.3, is often captured under general regulatory filings or specific transaction/insider categories. Given the options, this document is a regulatory disclosure concerning insider/significant shareholder activity during a potential M&A event (Takeover Code). Since there is no specific code for 'Takeover Disclosure Form 8.3', and it details personal dealings/positions related to an offer, it is closely related to insider trading disclosures (DIRS) or M&A activity (TAR). However, Form 8.3 is a specific regulatory filing mandated by the Takeover Panel, making it a type of regulatory announcement. Since it details dealings by a major shareholder/controller during a takeover scenario, it fits best under the umbrella of M&A Activity (TAR) or a general Regulatory Filing (RNS). Given the context of the Takeover Code and the involvement of an offeror/offeree, TAR (M&A Activity) is highly relevant, but DIRS (Director's Dealing) is for directors/executives. Since this is a major shareholder disclosure under the Takeover Code, and it details dealings, it is a specific type of regulatory filing. Given the options, and recognizing that this is a mandatory disclosure related to a takeover situation, it is a specific regulatory filing. If we must choose the closest fit among the provided definitions, it is a regulatory filing related to a transaction/event. Since it is a formal disclosure required by the Takeover Panel, it is a Regulatory Filing (RNS). If the focus was purely on the transaction itself, TAR might apply, but this is the *disclosure form* itself. I will classify it as RNS as the most appropriate general regulatory filing category for mandatory disclosures not covered elsewhere, although it is highly specific to takeover rules.
2023-11-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 5755T' and contains standardized tables related to share ownership changes, specifically referencing 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in major shareholdings, which corresponds directly to the definition of 'Major Shareholding Notification' (MRQ). Although it mentions RNS at the end, the core content is the TR-1 filing itself, not just an announcement of a report.
2023-11-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 5622T' and contains the standard formatting for a regulatory notification disseminated via RNS (Regulatory News Service). The content details a 'TR-1: Standard form for notification of major holdings' concerning an acquisition or disposal of voting rights by Societe Generale, crossing a threshold on 14-Nov-2023. This specific type of filing, reporting changes in significant share ownership, directly matches the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-11-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly labeled with "RNS Number" and contains standard regulatory disclosure tables regarding changes in major shareholdings (TR-1 form). The content details the acquisition/disposal of voting rights by Bank of America Corporation and its subsidiaries, crossing a notification threshold. This type of filing, which reports insider/major shareholder transactions, corresponds to the 'Director's Dealing' (DIRS) or 'Major Shareholding Notification' (MRQ) categories. Since this is a notification of a change in significant share ownership (crossing thresholds, as detailed in Section 7 and 8), the most appropriate classification is Major Shareholding Notification (MRQ). Although it is distributed via RNS, MRQ is more specific than the general RNS fallback.
2023-11-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 5370T' and contains the standard boilerplate text indicating it is provided by RNS, the news service of the London Stock Exchange. The content itself is a 'TR-1: Standard form for notification of major holdings' filed by Societe Generale regarding an acquisition of voting rights in Dechra Pharmaceuticals PLC, crossing a threshold (from 8.39% to 9.32%). This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is an RNS filing, MRQ is the more specific category for this content type.
2023-11-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 5301T' and contains the standard boilerplate text indicating it is provided by RNS, the news service of the London Stock Exchange. The content itself is a 'TR-1: Standard form for notification of major holdings' detailing an acquisition or disposal of voting rights by UBS Group AG. This type of mandatory disclosure regarding changes in significant share ownership thresholds fits the definition of Major Shareholding Notification (MRQ). Although it is an RNS filing, MRQ is the more specific and appropriate category.
2023-11-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.